Telix Pharmaceuticals chair steps down

Radiopharmaceutical giant Telix Pharmaceuticals (ASX:TLX) announced the immediate resignation of board Chair and Non-Executive Director Tiffany Olson.

The company confirmed that Mark Nelson, currently a non-executive director, has assumed the role of interim chair to ensure a seamless transition during what leadership describes as a "pivotal year" for the firm.

The board is reportedly in the "advanced stages" of a recruitment process to appoint new directors to fill the vacancy.

Despite the sudden departure, Nelson emphasised that the company's strategic roadmap remains intact, noting that Telix possesses an "exceptionally strong commercial business" and a robust development pipeline.

"We support Tiffany's personal decision and extend our sincere thanks for her service. This does not impact on the delivery of near-term milestones and the long-term growth strategy of the company," Nelson stated.

At the time of reporting, Telix Pharmaceuticals' share price was $10.15.